Understanding Oral SERDs in Breast Cancer Care is a multi-part educational video series created to support medical oncologists and multidisciplinary care teams in making evidence-based, patient-centered decisions for the management of ER-positive, HER2-negative breast cancer, with a particular focus on integrating oral selective estrogen receptor degraders (SERDs) into clinical practice. The series emphasizes biomarker-driven care, including ESR1 mutation testing, treatment selection across lines of therapy, monitoring and management of adverse events, and coordination of care across practice settings.
Virginia Kaklamani, MD, DSc, from UT Health San Antonio MD Anderson Cancer Center, and Seth Wander, MD, PhD, from Massachusetts General Hospital and Harvard Medical School, discuss the current landscape and future direction of oral SERDs. Watch the four-video series for insights and best practices to manage this treatment option.
Learning Objectives:
Upon completion of this activity, participants should be better able to:
- Introduce oral SERDs and their clinical rationale for treating ER-positive, HER2-negative breast cancer, particularly in the context of ESR1 mutations.
- Guide therapy selection and patient monitoring using current clinical data and real-world considerations.
- Promote multidisciplinary collaboration and seamless integration of biomarker testing and treatment decision-making across care settings.
Made possible with support from Menarini-Stemline.